Ankylosing Spondylitis Clinical Trials

It’s Time to Stand Up to Ankylosing Spondylitis! Take Part in Research of an Oral Investigational Medication for Ankylosing Spondylitis If you are still suffering from the pain and stiffness of ankylosing spondylitis (AS) symptoms despite treatment, you may want to consider participating in a research study of an oral ...

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).  

Randomized, Double-Blind, Parallel-Group, Multi-center study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with AS who are randomized to dose escalation after not achieving inactive disease during an initial 16 weeks of open-label tx w/secukinumab 150 mg (ASLeap)  

24-Week trial comparing treatment with Study Medicine vs. placebo. Patient Inclusion Criteria: Age >/= 18 Diagnosis of definite AS Active AS Inadequate response to treatment. Patient Exclusion Criteria: Major Surgery within 8 weeks prior to screening Inflammatory Disease other than AS Treatment with Investigational Medication within 4 weeks Hepatitis B, ...

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).

This longitudinal cohort study is aiming to follow 60 persons with ankylosing spondylitis during 18 months. Assessments will be conducted at baseline and every 6 months. An healthy control group of 30 persons will be included and age and sex matched to the first 30 patients.

The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis. Results of this study may be pooled with the results of a separate study being conducted in participants with ...

This post-marketing study will evaluate safety and efficacy profile of golimumab (a fully human anti-Tumour Necrosis Factor alpha [TNF-alpha] monoclonal antibodies [mAb], administered subcutaneously) in a real-world in Indian participants with active spondyloarthropathy of ankylosing spondylitis (AS) or psoriatic arthritis (PsA). AS is a chronic inflammatory disease of unknown etiology ...

A study to describe the one-year persistence (participants still treated by Flixabi at 12 Months) in participants treated by Flixabi (infliximab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) [adults and children] and Ulcerative ...

An observational study investigating the utilisation and effectiveness of originator and biosimilar anti-TNF agents in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.